How to Handle Adverse Effects Associated with Immune Checkpoint Inhibitors

The American Society of Clinical Oncology released guidelines on management of immune-related adverse effects in patients treated with immune checkpoint inhibitor therapy.

As immune checkpoint inhibitor (ICPi) therapy is growing more common for patients with cancer, nurses and other medical staff need to know the right ways to manage immune-related adverse effects. In February 2018, the American Society of Clinical Oncology (ASCO) released guidelines to help standardize and share appropriate responses.

An expert panel reviewed 204 evidence-based publications; however, because there is little high-quality evidence on management of these events, recommendations are based on expert consensus.

The ASCO panel created a 38-page summary of recommendations for diagnosing and managing adverse effects associated with ICPi treatment. In general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, with the exception of neurologic, hematologic, and cardiac toxicities.

Therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert to grade 1 or less.

Grade 3 toxicities generally warrant discontinuation of ICP is and the initiation of high-dose corticosteroids, with tapering over 4-6 weeks. Patients with unresolved grade 3 toxicities should be referred to a dermatologist.

Permanent discontinuation of ICP is is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement. Patients with grade 4 toxicities require hospital admission and prompt evaluation by a dermatologist. Patient and family members should receive education about immunotherapies, their mechanism of action, and associated adverse effects to report.

Supportive care guidelines from ASCO offers additional information, including a slide set and patient information sheet.

Related Videos
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
How To Respond When a Patient on Chemotherapy Presents With Pulmonary Embolism
Related Content
© 2023 MJH Life Sciences

All rights reserved.